A membrane channel is a family of proteins that allows the movement of ions, water or other solutions to pass through the membrane. These findings are being published in the Nov. 10, 2014, edition of the journal Cancer Cell. …
Prostate cancer is the most commonly diagnosed non-skin cancer in the United States, and it is second only to lung cancer as the leading cause of cancer deaths in American men. An estimated 233,000 new cases of prostate cancer will be diagnosed in the United States in 2014, and an estimated 29,000 will die of the disease. More than 2 million men are currently living with prostate cancer in the United States…
The researchers, based at the University of Wolverhampton, studied 24 breast cancers that had spread to the brain, along with samples from the original breast tumour, and found a handful of genes with faulty switches. Crucially, two of the genetic switches became faulty early on in the development of breast cancer, suggesting they may be an early warning signal for tumours that will spread to the brain. The scientists are now working to develop a blood test that might be able to detect these signals at an early stage, before the disease has spread. …
Around 5,000 cases of DCIS, a condition where cancerous cells are contained within the milk ducts of the breast, are diagnosed each year in the UK, with two thirds diagnosed through breast screening. If left untreated, up to half of DCIS cases could progress into invasive breast cancer, but it is not possible to say which ones, so all women are offered treatment. …
Up to one in six patients with esophageal cancer were found to have EGFR duplication in their tumor cells and taking the drug gefitinib, which targets this fault, boosted their survival by up to six months, and sometimes beyond. This is the first treatment for advanced esophageal cancer shown to improve survival in patients whose initial course of chemotherapy treatment has failed. It is also the first time a targeted treatment of any kind has proved effective in this disease, although chemotherapy and some targeted drugs have shown benefit in the second line treatment of other cancers of the digestive system including stomach cancer…
A team of scientists at the Max Planck Institute of Molecular Physiology in Germany has uncovered a new strategy and new potential drug to target an important signalling protein in cells called Ras, which is faulty in a third of cancers. When the Ras protein travels from the centre of a cell to the cell membrane, it becomes ‘switched on’ and sends signals which tell cells to grow and divide. …
The researchers, based at the University of Wolverhampton, studied 24 breast cancers that had spread to the brain, along with samples from the original breast tumour, and found a handful of genes with faulty switches. Crucially, two of the genetic switches became faulty early on in the development of breast cancer, suggesting they may be an early warning signal for tumours that will spread to the brain. The scientists are now working to develop a blood test that might be able to detect these signals at an early stage, before the disease has spread. Up to 30 per cent of breast cancers will eventually spread to the brain, often many years after the first tumour was treated…
The team of researchers led by Paul Hofman used a blood test developed during French research, which isolates all types of tumour cells from the bloodstream, without any loss, leaving them intact. The team studied a group of 245 people without cancer, including 168 patients at risk of later developing lung cancer because they had Chronic Obstructive Pulmonary Disease (COPD). Participants systematically underwent the blood test and standard diagnostic imaging tests…
The researchers, from the University of Cambridge and Addenbrooke’s Hospital in Cambridge, found unique molecular fingerprints for 11 types of children’s tumours, which could be used to develop blood tests to diagnose these cancers. This may eventually lead to a quicker, more accurate way to diagnose tumours, and could also reduce the need for children to undergo surgery to get a diagnosis one day. The research was funded by Sparks, the children’s medical research charity, and Cancer Research UK. Each year almost 1,600 children are diagnosed with cancer in the UK…
This is the first time that cancer-specific blood markers have been comprehensively reviewed and identified for further clinical development. This study, by the UK Early Cancer Detection Consortium, funded by Cancer Research UK, has analysed 19,000 scientific papers and found more than 800 biomarkers. The aim of this research is to develop a screening test from a single blood sample for multiple cancer types. All cancers produce markers in the blood, so it could be feasible to develop a general screening test for many different forms of the disease. …